<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03125486</url>
  </required_header>
  <id_info>
    <org_study_id>207616</org_study_id>
    <nct_id>NCT03125486</nct_id>
  </id_info>
  <brief_title>Compassionate Use for Subcutaneous (SC) Belimumab</brief_title>
  <official_title>Compassionate Use for Subcutaneous (SC) Belimumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      GlaxoSmithKline (GSK) have submitted a Biologic License Application (BLA) for the&#xD;
      subcutaneous formulation of belimumab which is currently under review by the Food and Drug&#xD;
      Administration (FDA). The goal of this individual patient compassionate use supply is to&#xD;
      provide a patient with subcutaneous belimumab for the period of 1 year or until the&#xD;
      subcutaneous formulation of belimumab becomes approved for use by the FDA and is commercially&#xD;
      available to this patient, whichever is sooner. You can access GSK's Policy on Compassionate&#xD;
      via http://www.gsk.com/media/3368/compassionate-use.pdf.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Systemic Lupus Erythematosus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC belimumab 200 mg</intervention_name>
    <description>Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        This is a protocol to support an emergency IND for compassionate use in one patient&#xD;
        requiring use of belimumab subcutaneous for SLE treatment (lacks venous access and cannot&#xD;
        receive IV belimumab).&#xD;
&#xD;
        Eligibility criteria is based on the following, as provided within GSK's policy on&#xD;
        compassionate use:&#xD;
&#xD;
          -  The illness being treated is life threatening or seriously debilitating.&#xD;
&#xD;
          -  There are no satisfactory alternative treatments (confirmed by the HCP).&#xD;
&#xD;
          -  There is sufficient evidence to believe the benefit to the patient justifies the risk&#xD;
             You can access GSK's Policy on Compassionate via&#xD;
             http://www.gsk.com/media/3368/compassionate-use.pdf.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>subcutaneous Belimumab</keyword>
  <keyword>Individual Patient Compassionate Use</keyword>
  <keyword>SLE</keyword>
  <keyword>GSK1550188</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

